• Search
  • Login
  • Register
Menu
  • Last issue
  • Home
  • News
  • CongressUpdate
  • Guidelines
  • Specials
  • Links
  • Reimbursement News
All
  • All
  • BJH articles
  • Blog articles
  • Specials
Forgot Password? Not a member yet? Register here

Category

All
  • Alle
  • General
  • Healthy Living
  • Pharma News
  • Health of Tomorrow
  • Viewpoints
  • Art Corner
  • Fundraising
  • Prevention
  • Science
  • Clinical trials
  • Clinical practice
  • Corona
  • Medical Research
  • Health Innovation
  • Art on View
  • Podcasts
  • Therapy
  • Editor's pick
  • Covid-19
  • Society Announcement
  • Reimbursement News
  • Congress News

Specialty

All
  • Alle
  • YESCARTA
  • BEKEMV
  • NPLATE
Clinical trials

First-line triple combination chemotherapy for patients with AML

subscribe Latest issue All issues Newsletters
Index latest issue
  • INTRODUCTION
  • Advancements in thrombophilia testing: The role of multi-gene panels in venous thromboembolism
  • The role of UBTF-TD mutations in paediatric acute myeloid leukaemia and myelodysplastic syndrome
  • Desensitisation as treatment option in patients with drug hypersensitivity
  • HMB-001: Novel treatment for Glanzmann thrombasthenia
  • Anti-IL6 receptor antibody for the treatment of immune checkpointrelated hemophagocytic lymphohistiocytosis
  • Highlights from EBMT 2025
  • Journal scan
  • New haematology reimbursements in Belgium
Clinical trials

Utomilumab improves the efficacy of CAR-T cell therapy for advanced large B-cell lymphoma

Pharma News

RMAT designation to obecabatagene autoleucel by FDA for patients with acute lymphoblastic leuk...

Medical Research

Leukaemia remission for a decade after CAR-T cell therapy

Medical Research

LSD1 inhibition sensitizes AML cells to MAPK inhibitor

ASH 2021

Axicabtagene ciloleucel: potential new second-line standard of care for patients with relapsed...

ASH 2021

Mosunetuzumab: effective and well-tolerated in the treatment of relapsed/refractory follicular...

Previous 23 24 25 26 27 28 29 Next
Top

Join our newsletter

  • This field is for validation purposes and should be left unchanged.
  • About BJH
  • Advertisements & sponsoring
  • Vacancies
  • Disclaimer
  • Privacy
  • Contact

BJH is published by Ariez International BV, Westzijde 22, 1506 EE Zaandam, The Netherlands

© BJH 2025